Lördag 25 Januari | 13:48:09 Europe / Stockholm

Kalender

Tid*
2025-12-03 N/A Årsstämma
2025-11-05 08:00 Bokslutskommuniké 2025
2025-08-22 07:00 Kvartalsrapport 2025-Q3
2025-05-07 07:00 Kvartalsrapport 2025-Q2
2025-01-30 07:00 Kvartalsrapport 2025-Q1
2024-12-05 - X-dag ordinarie utdelning AMBU B 0.38 DKK
2024-12-04 - Årsstämma
2024-11-05 - Bokslutskommuniké 2024
2024-08-30 - Kvartalsrapport 2024-Q3
2024-05-14 - Kvartalsrapport 2024-Q2
2024-01-30 - Kvartalsrapport 2024-Q1
2023-12-14 - X-dag ordinarie utdelning AMBU B 0.00 DKK
2023-12-13 - Årsstämma
2023-11-08 - Bokslutskommuniké 2023
2023-08-31 - Kvartalsrapport 2023-Q3
2023-05-03 - Kvartalsrapport 2023-Q2
2023-02-07 - Kvartalsrapport 2023-Q1
2022-12-15 - X-dag ordinarie utdelning AMBU B 0.00 DKK
2022-12-14 - Årsstämma
2022-11-15 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q3
2022-05-10 - Kvartalsrapport 2022-Q2
2022-02-08 - Kvartalsrapport 2022-Q1
2021-12-15 - X-dag ordinarie utdelning AMBU B 0.29 DKK
2021-12-14 - Årsstämma
2021-11-09 - Bokslutskommuniké 2021
2021-08-17 - Kvartalsrapport 2021-Q3
2021-05-12 - Kvartalsrapport 2021-Q2
2021-01-27 - Kvartalsrapport 2021-Q1
2020-12-10 - X-dag ordinarie utdelning AMBU B 0.29 DKK
2020-12-09 - Årsstämma
2020-11-11 - Bokslutskommuniké 2020
2020-08-26 - Kvartalsrapport 2020-Q3
2020-05-05 - Kvartalsrapport 2020-Q2
2020-02-04 - Kvartalsrapport 2020-Q1
2019-12-18 - X-dag ordinarie utdelning AMBU B 0.38 DKK
2019-12-17 - Årsstämma
2019-11-13 - Bokslutskommuniké 2019
2019-08-22 - Kvartalsrapport 2019-Q3
2019-05-01 - Kvartalsrapport 2019-Q2
2019-01-31 - Kvartalsrapport 2019-Q1
2018-12-13 - X-dag ordinarie utdelning AMBU B 0.40 DKK
2018-12-12 - Årsstämma
2018-11-13 - Bokslutskommuniké 2018
2018-08-23 - Kvartalsrapport 2018-Q3
2018-05-07 - Kvartalsrapport 2018-Q2
2018-01-31 - Kvartalsrapport 2018-Q1
2018-01-03 - Split AMBU B 1:5
2017-12-14 - X-dag ordinarie utdelning AMBU B 1.85 DKK
2017-12-13 - Årsstämma
2017-09-30 - Bokslutskommuniké 2017
2017-08-23 - Kvartalsrapport 2017-Q3
2017-05-02 - Kvartalsrapport 2017-Q2
2017-02-01 - Kvartalsrapport 2017-Q1
2016-12-13 - X-dag ordinarie utdelning AMBU B 1.55 DKK
2016-12-12 - Årsstämma
2016-09-30 - Bokslutskommuniké 2016
2016-08-19 - Kvartalsrapport 2016-Q3
2016-05-03 - Kvartalsrapport 2016-Q2
2016-01-29 - Kvartalsrapport 2016-Q1
2015-12-11 - X-dag ordinarie utdelning AMBU B 0.95 DKK
2015-12-10 - Årsstämma
2015-11-11 - Bokslutskommuniké 2015
2015-08-19 - Kvartalsrapport 2015-Q3
2015-05-06 - Kvartalsrapport 2015-Q2
2015-02-02 - Kvartalsrapport 2015-Q1
2014-12-23 - Split AMBU B 1:4
2014-12-18 - X-dag ordinarie utdelning AMBU B 3.75 DKK
2014-12-17 - Årsstämma
2014-11-13 - Bokslutskommuniké 2014
2014-08-20 - Kvartalsrapport 2014-Q3
2014-05-02 - Kvartalsrapport 2014-Q2
2014-02-04 - Kvartalsrapport 2014-Q1
2013-12-13 - X-dag ordinarie utdelning AMBU B 1.25 DKK
2013-12-12 - Årsstämma
2013-09-30 - Bokslutskommuniké 2013
2013-08-20 - Kvartalsrapport 2013-Q3
2013-05-02 - Kvartalsrapport 2013-Q2
2013-02-05 - Kvartalsrapport 2013-Q1
2012-12-14 - X-dag ordinarie utdelning AMBU B 3.00 DKK
2012-12-13 - Årsstämma
2012-09-30 - Bokslutskommuniké 2012
2012-08-23 - Kvartalsrapport 2012-Q3
2012-05-03 - Kvartalsrapport 2012-Q2
2012-02-09 - Kvartalsrapport 2012-Q1
2011-12-16 - X-dag ordinarie utdelning AMBU B 2.00 DKK
2011-12-15 - Årsstämma
2011-09-30 - Bokslutskommuniké 2011
2011-08-25 - Kvartalsrapport 2011-Q3
2011-05-09 - Kvartalsrapport 2011-Q2
2011-02-07 - Kvartalsrapport 2011-Q1
2010-12-17 - X-dag ordinarie utdelning AMBU B 2.50 DKK
2009-12-17 - X-dag ordinarie utdelning AMBU B 1.50 DKK
2005-03-01 - Split AMBU B 1:2
2004-02-10 - Split AMBU B 1:10

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Ambu är verksamt inom medicinteknik. Bolaget utvecklar och marknadsför diagnostisk utrustning för aktörer inom vård- och omsorg. Störst verksamhet återfinns inom utvecklingen av lösningar för endoskopi, gastroskopi och patientövervakning. Verksamhet innehas på global nivå med störst närvaro inom Europa och Nordamerika. Ambu grundades 1937 och har sitt huvudkontor i Ballerup, Danmark.
2025-01-09 18:28:41

9.1.2025 18:28:39 CET | Ambu A/S | Inside information

Today, Ambu announces preliminary Q1 2024/25 results and raises expectations for the full 2024/25 financial year. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).

The raised organic growth outlook is mainly driven by better-than-expected revenue growth in Anaesthesia & Patient Monitoring, driven by price increases and solid volume growth. In addition, the raised outlook is supported by continued strong organic growth in Endoscopy Solutions, driven by solid pulmonology momentum and continued strong growth across urology, ear-nose-throat (ENT) and gastroenterology (GI).

Furthermore, the raised EBIT margin outlook is driven by continued strengthened operational leverage in OPEX from organic revenue growth and is also positively affected by the strengthening of the USD/DKK currency, relative to the previous outlook from 5 November 2024. Finally, the updated EBIT guidance reflects the increased expectations for organic revenue growth and also includes an expectation of continued investments to support growth for the remainder of the financial year.


PRELIMINARY AND UNAUDITED FINANCIAL HIGHLIGHTS FOR Q1 2024/25
Last year’s comparative figures are stated in brackets.

  • Revenue was DKK 1,510m (DKK 1,254m), with organic revenue growth of 19.5% (14.2%), mainly driven by continued strong growth in both pulmonology and urology, ENT and GI within Endoscopy Solutions, delivering a combined total growth of 20.6% (25.1%), supplemented by strong growth of 17.8% (1.2%) in Anaesthesia & Patient Monitoring, driven by price increases and solid volume growth, combined with a weaker comparison quarter. Total reported growth for the quarter was 20.4% (10.9%).
  • EBIT before special items was DKK 243m (DKK 126m), with an EBIT margin before special items of 16.1% (10.0%). The strengthened EBIT margin was primarily driven by operational leverage on OPEX from organic growth, as well as the continued strengthening of the USD/DKK currency, although partially offset by increased investments aimed at driving organic growth.


REVISED OUTLOOK FOR THE FISCAL YEAR 2024/25
Driven by the development in the first quarter of the 2024/25 financial year, Ambu’s 2024/25 financial outlook is set as per below:

OUTLOOK FY 2024/25

9 JAN 2025

5 NOV 2024

Organic revenue growth

11-14%

10-13%

EBIT margin before special items

13-15%

12-14%

In addition, Ambu now expects the organic revenue growth for Anaesthesia & Patient Monitoring to reach mid-to-high single digits (previously mid-single digits).

Ambu’s expectations for the Endoscopy Solutions organic revenue growth are unchanged at +15%. Similarly, Ambu’s free cash flow expectations are maintained at DKK +500m.

Ambu will publish its full Q1 2024/25 interim results, as previously announced, on 30 January 2025.

Contacts

  • Anders Hjort, Head of Investor Relations, +45 2892 8881, anhj@ambu.com
  • Tine Bjørn Schmidt, Head of Corporate Communications, +45 2264 0697, tisc@ambu.com

About Ambu A/S

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in Europe, North America, Latin America and Asia Pacific.

For more information, please visit Ambu.com.

Attachments